Nakamura Kentaro
Bioscience & Technology Development Center, FUJIFILM Corporation, Kanagawa/258-8577, Japan.
Curr Stem Cell Res Ther. 2019;14(1):52-56. doi: 10.2174/1574888X13666180912125157.
In the field of stem cell therapy, research on the application of mesenchymal stem cells (MSCs) has flourished because of the various functions. On the other hand, research on the method of cell transplantation has developed from the administration of cell suspensions to cell-sheet engineering and 3D technology. In the trend, a cell transplantation platform named CellSaic, which is a combination of xeno-free recombinant scaffolds in a cell aggregate-like shape, was developed. CellSaic is the cell transplantation platform that can prevent the central necrosis within cell aggregates by arranging the cells and petaloid pieces of recombinant peptide (RCP) in a mosaic. The prevention of central necrosis is the most significant advantage over other 3D culture systems. This review details the unique characteristics of CellSaic including safety examination results and describes its future application for MSC transplantation. Particularly, in the application of MSCs, it has been reported that the MSC CellSaics increased the effect on improving various symptoms compared with MSCs only in the application of the therapy to inflammatory bowel disease (IBD), cerebral infarction, bone cartilage regeneration in joints, and islet transplantation. In accordance with the "One Health" concept, it is anticipated that this technology is expected to contribute to companion animal therapy and human therapy in the future.
在干细胞治疗领域，由于间充质干细胞（MSCs）具有多种功能，其应用研究蓬勃发展。另一方面，细胞移植方法的研究已从细胞悬液给药发展到细胞片工程和3D技术。在此趋势下，开发了一种名为CellSaic的细胞移植平台，它是无动物源重组支架与细胞聚集体形状的组合。CellSaic是一种细胞移植平台，通过将细胞和重组肽（RCP）花瓣状片镶嵌排列，可防止细胞聚集体内部发生中央坏死。预防中央坏死是其相较于其他3D培养系统最显著的优势。本综述详细介绍了CellSaic的独特特性，包括安全性检查结果，并描述了其在MSC移植中的未来应用。特别是在MSCs的应用中，据报道，在炎症性肠病（IBD）、脑梗死、关节骨软骨再生和胰岛移植治疗中，与仅使用MSCs相比，MSC CellSaics增强了改善各种症状的效果。按照“同一健康”理念，预计该技术未来有望为伴侣动物治疗和人类治疗做出贡献。
